Usability and Functional Outcomes of the Obi3 Robotic Feeding Device Among People With Disabilities, Caregivers, and Providers: Mixed Methods Study.

The self-feeding impairment scale was developed internally by the manufacturer, has no published validity, reliability, or responsiveness data, and was rated by the same therapists who were study participants. The trial lasted one week; it says nothing about whether improvements hold, whether skills transfer, or whether caregiver burden changes over months. There was no control group, no randomisation, and no blinding, so the observed changes cannot be separated from novelty, practice effects, or the attention of a research team. The sample was small (50 enrolled, 42 completing surveys) and the target of 60 was not met. The manufacturer sponsored the study, coordinated it, and multiple authors are employees, consultants, or equity holders of the company. No objective nutritional, biomechanical, or meal-duration measures were collected. The authors state that the self-feeding improvements should be read as preliminary evidence of functional feasibility, not conclusive evidence of clinical efficacy.

The device manufacturer, DESĪN LLC, sponsored and coordinated the study. One author is Director of Clinical Affairs at DESĪN LLC and was also a paid consultant on the study; another is a paid employee and subinvestigator; a third holds equity in the company. A fourth author received compensation through a company supervised by the first author. All conflicts were reviewed by the IRB.

Do not read the 3.2-point drop in self-feeding impairment as proof the device restores feeding ability. The scale was built in-house by the manufacturer, has no published validity or reliability data, was rated by the same therapists who were study participants, the trial lasted one week, there was no control group, and the manufacturer funded and coordinated the work. The authors themselves call the result preliminary evidence of feasibility, not clinical efficacy.